Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
The MNK news page on Stock Titan aggregates company-issued updates and media coverage related to Mallinckrodt plc and its subsequent branded therapeutics identity, Keenova Therapeutics. Recent press releases describe Mallinckrodt as a global specialty pharmaceutical company with a Brands business focused on autoimmune and rare diseases and a Par Health business that includes generic drugs, sterile injectables and active pharmaceutical ingredients.
News items for MNK include announcements on corporate transactions, such as the completion of the merger between Mallinckrodt and Endo, Inc., and the spin-off of the combined generics and sterile injectables businesses under the Par Health name. These releases also explain that, moving ahead, Mallinckrodt will be known as Keenova Therapeutics, a branded therapeutics company focused on helping patients with rare or unaddressed conditions.
Investors and followers of MNK can find updates on financial results, including quarterly net sales and segment performance for Specialty Brands, Generics and Sterile Injectables as reported by the company. Other news covers developments in key branded products, such as Acthar Gel and XIAFLEX, as well as communications about clinical and medical affairs activities, including data presentations related to TERLIVAZ for hepatorenal syndrome.
Additional coverage includes leadership and governance announcements, such as board appointments and executive changes, along with guidance and commentary on the company’s strategy around its Brands and Par Health businesses. For users tracking MNK, this news feed provides a central view of the company’s own disclosures on its therapeutic focus, portfolio evolution, corporate structure and branded transition to Keenova Therapeutics.
Keenova (MNK) announced first-time publication of a Phase 4 retrospective analysis of XIAFLEX® (collagenase clostridium histolyticum) for recurrent Dupuytren contracture after surgery.
The multicenter review covered patients treated between January 2010 and August 2020 across 10 U.S. clinical centers, measured joint contracture changes within 12 months, and found adverse events consistent with prior CCH reports.
Keenova (NASDAQ:MNK) presented previously unpublished Phase 2 extension data on collagenase clostridium histolyticum (CCH) for plantar fibromatosis at the ACFAS Annual Meeting Feb 24–27, 2026. Findings suggest a safety profile consistent with earlier Phase 2 results and support potential long‑term safety, efficacy, and durability.
Keenova is conducting a pivotal Phase 3 trial for CCH in plantar fibromatosis, with topline results expected mid‑2026.
Keenova (NASDAQ:MNK) announced a peer‑reviewed manuscript in Journal of Foot and Ankle Surgery reporting real‑world treatment patterns for plantar fibromatosis and highlighted persistent symptoms after conservative care. The company said it is actively evaluating collagenase clostridium histolyticum (CCH) in a Phase 3 trial currently underway (Feb 16, 2026).
The study notes no FDA‑approved nonsurgical options and calls for more research on long‑term outcomes and effective therapies.
Keenova (NASDAQ:MNK) announced it reached a milestone on Jan 21, 2026: 100,000 patients have been prescribed XIAFLEX to treat Peyronie's disease. XIAFLEX is described as the only FDA‑approved nonsurgical therapy for adult men with a palpable plaque and curvature >30 degrees at treatment start. Keenova plans expanded 2026 awareness campaigns, amplified patient voices on social media, and broader access to a mixed‑reality injection simulator for providers.
Keenova Therapeutics (NASDAQ:MNK) announced a Keenova‑sponsored presentation on Dupuytren's contracture (DC) at the American Association for Hand Surgery Annual Meeting, January 13–17, 2026. The presentation, led by Dr. Philip Blazar, reports results from a national patient survey on perceptions, attributes, and satisfaction with DC diagnosis and treatment options including surgery, collagenase clostridium histolyticum (CCH/XIAFLEX), and needle aponeurotomy.
The analysis highlights gaps in patient awareness and opportunities to improve education and patient–provider conversations to support earlier recognition and better treatment outcomes.
Keenova Therapeutics (NASDAQ:MNK) announced management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 10:00 a.m. GMT (5:00 a.m. ET). A live webcast and archived replay will be available via the company’s Investor Relations website at www.keenova.com.
The presentation provides investors a scheduled opportunity to hear management commentary and view the webcast recording.
Mallinckrodt (NYSE:MNK) reported third-quarter 2025 combined net sales of $753.1 million, a 49.0% increase versus Q3 2024, reflecting two months of Endo inclusion and Acthar® Gel strength.
Specialty Brands sales were $416.0 million (45.5% growth), including Acthar Gel net sales of $181.4 million (+43.5%) and XIAFLEX net sales of $90.1 million. Generics and Sterile Injectables totaled $337.1 million (53.6% growth).
GAAP net loss was $291.1 million; adjusted EBITDA was $111.3 million. Management raised full-year Acthar Gel growth guidance to 30%–35% and provided Q4 2025 guidance of $485M–$505M net sales and $155M–$165M adjusted EBITDA. Post-merger synergy targets: $75M run-rate first 12 months and $150M by year three.
Keenova Therapeutics (formerly Mallinckrodt, NYSE: MNK) completed the spin-off of Par Health on Nov 10, 2025 and rebranded to focus on branded therapeutics for rare and unmet conditions.
The company reported a 2024 pro-forma combined revenue of $1.7 billion, employs >1,600 people, and lists flagship products Acthar Gel and XIAFLEX. Keenova is headquartered in Dublin with a U.S.-focused commercial and manufacturing footprint.
The company intends to pursue a NYSE listing in 2026 and expects to conduct a public offering to facilitate the listing, subject to board approval and other conditions.
Mallinckrodt (NYSE:MNK) will present four posters, including one AASLD Poster of Distinction, at The Liver Meeting (AASLD) in Washington, D.C., Nov 7–11, 2025.
Presentations focus on hepatorenal syndrome (HRS) and TERLIVAZ (terlipressin), the first FDA-approved therapy to improve kidney function in adults with HRS‑AKI. Session: Portal Hypertension and Other Complications of Cirrhosis on Nov 8, 2025. Poster numbers: #2285 (Distinction), #2401, #2315, #2380. Key prescribing notes: patients with serum creatinine >5 mg/dL are unlikely to benefit. Important safety: boxed warning for serious or fatal respiratory failure; contraindications include hypoxia and active ischemia.
Mallinckrodt (NYSE:MNK) will report its third quarter 2025 financial results on Monday, November 10, 2025 before market open.
The company will host a conference call the same day at 8:00 a.m. ET with an audio webcast available in the Investor Relations section at ir.mallinckrodt.com under Events & Presentations. Participants can register to receive a dial-in number and personalized PIN; attendees are advised to join 10 minutes early. A replay of the webcast will be available after the event.